Anti HLA-G specific antibodies
The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.
1. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject an anti-human leukocyte antigen G (HLA-G) antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises:
(a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO: 8, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO: 10, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 12; and
(b) a light chain variable region (VL), which comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO: 2, a light chain complementarity determining region 2 (LC CDR2) of sequence KVS and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 5.
2. The method of claim 1 , wherein the VH comprises SEQ ID NO: 64 and the VL comprises SEQ ID NO: 63.
3. The method of claim 2 , wherein the antibody is a full-length immunoglobulin G comprising two heavy chains and two light chains.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment is humanized or chimeric.
5. The method of claim 1 , wherein the VH, the VL, or both the VH and VL comprise human immunoglobulin framework region sequences.
6. The method of claim 1 , wherein the antibody comprises an immunoglobulin constant region.
7. The method of claim 1 , wherein the antigen-binding fragment is a Fv, a dsFv, a scFv, a Fab, a Fab′, or a F(ab′) 2 .
8. The method of claim 1 , wherein the antibody is monoclonal.
9. The method of claim 1 , wherein the antibody or antigen-binding fragment is linked to a cytotoxic agent.
10. The method of claim 1 , wherein the cancer is bladder cancer, kidney cancer, urogenital cancer, melanoma, leukemia, basal cell carcinoma, breast cancer, malignant mesothelioma, clear cell renal carcinoma, retinoblastoma, spinous cell carcinoma, in situ carcinoma, colorectal cancer, ovarian carcinoma, cutaneous T cell lymphoma, endometrial adenocarcinoma, classical Hodgkin lymphoma, lung carcinoma, cutaneous B cell lymphoma, gastric cancer, ampullary cancer, biliary cancer, pancreatic ductal adenocarcinoma or esophageal squamous cell carcinoma.
11. The method of claim 1 , wherein the subject is human.
12. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-human leukocyte antigen G (HLA-G) antibody or an antigen-binding fragment thereof, and a pharmaceutical carrier;
wherein the antibody or antigen-binding fragment comprises:
(a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO: 8, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO: 10, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 12; and
(b) a light chain variable region (VL), which comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO: 2, a light chain complementarity determining region 2 (LC CDR2) of sequence KVS and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 5.
13. The method of claim 12 , wherein the VH comprises SEQ ID NO: 64 and the VL comprises SEQ ID NO: 63.
14. The method of claim 13 , wherein the antibody is a full-length immunoglobulin G comprising two heavy chains and two light chains.
15. The method of claim 12 , wherein the antibody or antigen-binding fragment is humanized or chimeric.
16. The method of claim 12 , wherein the VH, the VL, or both the VH and VL comprise human immunoglobulin framework region sequences.
17. The method of claim 12 , wherein the antibody comprises an immunoglobulin constant region.
18. The method of claim 12 , wherein the antigen-binding fragment is a Fv, a dsFv, a scFv, a Fab, a Fab′, or a F(ab′) 2 .
19. The method of claim 12 , wherein the antibody is monoclonal.
20. The method of claim 12 , wherein the antibody or antigen-binding fragment is linked to a cytotoxic agent.
21. The method of claim 12 , wherein the cancer is bladder cancer, kidney cancer, urogenital cancer, melanoma, leukemia, basal cell carcinoma, breast cancer, malignant mesothelioma, clear cell renal carcinoma, retinoblastoma, spinous cell carcinoma, in situ carcinoma, colorectal cancer, ovarian carcinoma, cutaneous T cell lymphoma, endometrial adenocarcinoma, classical Hodgkin lymphoma, lung carcinoma, cutaneous B cell lymphoma, gastric cancer, ampullary cancer, biliary cancer, pancreatic ductal adenocarcinoma or esophageal squamous cell carcinoma.
22. The method of claim 12 , wherein the subject is human.
23. The method of claim 12 , wherein the pharmaceutical carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration.